Peter Ordentlich
Founder at SYNDAX PHARMACEUTICALS, INC.
Net worth: 6 307 $ as of 2024-03-30
Profile
Peter Ordentlich is the founder of Syndax Pharmaceuticals, Inc., which was founded in 2005.
He currently holds the title of Chief Scientific Officer at Syndax Pharmaceuticals, Inc. Dr. Ordentlich also held the position of Principal at The Salk Institute for Biological Studies and Research Scientist at X-Ceptor Therapeutics, Inc. In terms of education, Dr. Ordentlich obtained undergraduate and doctorate degrees from the University of Pennsylvania.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2023-02-14 | 265 ( 0.00% ) | 6 307 $ | 2024-03-30 |
Peter Ordentlich active positions
| Companies | Position | Start |
|---|---|---|
| SYNDAX PHARMACEUTICALS, INC. | Founder | 2005-10-10 |
Former positions of Peter Ordentlich
| Companies | Position | End |
|---|---|---|
X-Ceptor Therapeutics, Inc.
 X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Corporate Officer/Principal | - |
| The Salk Institute for Biological Studies | Corporate Officer/Principal | - |
Training of Peter Ordentlich
| University of Pennsylvania | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| SYNDAX PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
X-Ceptor Therapeutics, Inc.
X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Commercial Services |
- Stock Market
- Insiders
- Peter Ordentlich
